Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12561 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Oct 2026, 03:17 UTC
2557
Shown in this register
most recently authorised
12,561
Total on CTIS
full historical archive
776
Phase III
within the shown window
Top member states
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555
Narrow the registerReset
Phase
Phase I 573 Phase I/II 216 Phase II 728 Phase III 776 Phase IV 264
Lead sponsor
AstraZeneca AB 66 Merck Sharp & Dohme LLC 50 Pfizer Inc. 48 Assistance Publique Hopitaux De Paris 48 Novartis Pharma AG 43
Member state
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555 Belgium 451 Czechia 340
All 28 states

Trials with a site in France

917 of 2557 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
DrugsEribulin·Gemcitabine·Paclitaxel·Carboplatin
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase II
Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON
2025-524343-13-00Leber's Hereditary Optic Neuropathy
Centre Hospitalier Universitaire D'Angers
Eye Diseases
France
03/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
2025-522383-33-00Pulmonary fibrosis, Interstitial lung diseases, Familial pu…
Boehringer Ingelheim International GmbH
Respiratory Tract Diseases
Belgium, Spain, Netherlands, Italy, Germany, France
03/03/2026
Phase I
C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.
2025-521756-39-00Non-muscle invasive bladder cancer (NMIBC)
Pfizer Inc.
Neoplasms
France, Spain
02/03/2026
Phase II
A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)
2025-521437-88-00head and neck squamous cell carcinoma
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France
02/03/2026
Phase II
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study
2025-522060-32-00STEMI (ST elevated Myocardial Infarction)
DrugAdenosine
CorFlow Therapeutics AG, CorFlow Therapeutics AG
Cardiovascular Diseases
Netherlands, Spain, France
02/03/2026
Phase II
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
2025-522896-27-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
2025-522695-83-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Spain, France, Belgium, Sweden, Germany, Italy
02/03/2026
Phase II
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
2025-523100-77-00Ulcerative Colitis
Pfizer Inc.
Digestive System Diseases
Finland, Poland, France, Germany, Italy, Slovakia
27/02/2026
Phase III
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial »
2024-511807-41-01Hemophagocytic lymphohistiocytosis (HLH)
DrugsEtoposide·Dexamethasone
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
27/02/2026
Phase I/II
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)
2025-522944-41-00Solid Tumours
DrugNivolumab
Pathios Therapeutics Limited
Not possible to specify
France, Spain
27/02/2026
Phase III
HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
2025-523079-44-00Turner Syndrome (TS), idiopathic short stature (ISS), short…
Ascendis Pharma Endocrinology Division A/S
Musculoskeletal Diseases
Germany, Spain, Italy, France, Romania
27/02/2026
Phase II
A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis
2025-524784-20-00Recurrent Pericarditis
Zomagen Biosciences Limited
Cardiovascular Diseases
Belgium, France, Greece
27/02/2026
Phase III
DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL (DARLENE)
2025-522687-33-00Stroke
Centre Hospitalier Universitaire De Lille
Nervous System Diseases
France
26/02/2026
Phase II
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
2024-516215-24-00TAkayasu ARteritiS
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
26/02/2026
Phase III
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
2024-520101-39-00TROP2 NMR-positive advanced or metastatic non-squamous non-…
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase I
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
2025-523297-16-00Non-Hodgkin Lymphoid Malignancies (NHLs)
Janssen Cilag International
Neoplasms
Belgium, France, Spain
26/02/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
2025-522835-32-00Suspected Invasive Mould Infection
Elion Therapeutics Inc.
Bacterial Infections and Mycoses
Belgium, France, Spain, Italy
26/02/2026
Phase III
ASPIRIN - Acetylsalicylic acid versus placebo in addition to a local non-steroidal anti-inflammatory drug in the treatment of thrombotic episodes in superficial venous malformations in children aged 6 to 17 years: a controlled randomised, double-blind, cross-over, multicenter trial
2024-517595-38-00Thrombotic episodes in superficial venous malformations in …
Centre Hospitalier Regional Universitaire De Tours
Cardiovascular Diseases
France
25/02/2026
Phase II
Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation. Multicenter, open-label, randomized phase II controlled trial.
2024-520131-33-00atrial fibrillation
Centre Hospitalier Universitaire Grenoble Alpes
Cardiovascular Diseases
France
25/02/2026
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00psoriatic arthritis (PsA)
DrugSonelokimab
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase I/II
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
2024-520238-31-01Advanced Lung Cancer
BioNTech SE
Neoplasms
Spain, France, Italy, Poland
24/02/2026
Phase III
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Dise…
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
2025-521037-86-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease
2025-521036-11-00Immune system disseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase II
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
2025-522204-24-00Neoplasms, Vomiting, Drug-Related Side Effects and Adverse …
Eli Lilly & Co.
Neoplasms
Romania, Spain, France, Italy
23/02/2026
Phase III
INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopen…
Incyte Corp.
Hemic and Lymphatic Diseases
Netherlands, Italy, Spain, France
23/02/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
DrugsFrexalimab·Tacrolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
DrugsZiftomenib·Cytarabine·Azacitidine·Venetoclax
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
2025-522544-40-00Hereditary transthyretin-mediated amyloidosis with polyneur…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
France, Italy, Greece, Spain, Sweden, Ireland, Cyprus, Portugal, Germany
20/02/2026
Phase I/II
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B
2025-523619-12-00Chronic Hepatitis B
Nchroma Bio Inc.
Virus Diseases
France
20/02/2026
Phase I
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
2025-521438-27-00advanced, unresectable and/or metastatic solid tumors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Sweden, France, Spain, Germany
19/02/2026
Phase I/II
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
2025-521164-36-00Patients with relapsed/refractory advanced/metastatic ovari…
Apmonia Therapeutics
Neoplasms
Belgium, France
19/02/2026
Phase I/II
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
2024-519412-13-00Canavan Disease, Canavan disease
Myrtelle Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
18/02/2026
Phase III
Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation
2023-509247-27-00Neonatal respiratory distress. Pain and discomfort
DrugDexmedetomidine
Centre Hospitalier Intercommunal Creteil
Anesthesia and Analgesia
France
18/02/2026
Phase III
A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
2025-520897-21-00Multiple Myeloma
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Norway, France, Spain
18/02/2026
Phase III
J2A-MC-GZPR: A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
2025-523283-21-00Peripheral Arterial Disease
Eli Lilly & Co.
Cardiovascular Diseases
Slovakia, Poland, France, Netherlands
17/02/2026
Phase III
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
2025-522873-12-00ER+, HER2- Advanced Breast Cancer
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
2025-522595-87-00Hematological Malignancies
DrugsEpcoritamab·Rituximab
Daiichi Sankyo Inc.
Neoplasms
France, Italy
16/02/2026
Phase II
A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome
2025-524008-32-00Capecitabine-induced hand and foot syndrome
Tarian Pharma
Skin and Connective Tissue Diseases
France
16/02/2026
Phase III
A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes: Victorion – RIDES
2025-521670-34-00Acute coronary syndrome (ST-elevation myocardial infarction…
Novartis Pharma AG
Cardiovascular Diseases
Germany, Hungary, Poland, France, Spain
16/02/2026
Phase III
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naïve Adult Participants Living With HIV 1
2025-522519-40-00HIV
Merck Sharp & Dohme LLC
Virus Diseases
France, Spain
16/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase I
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00Locally advanced unresectable or metastatic soft tissue sar…
Novartis Pharma AG
Neoplasms
Germany, Portugal, France, Spain, Denmark
16/02/2026
Phase I
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
2025-523826-41-00Dermatitis atopic
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase II
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
2025-521416-19-00Recurrence of Clostridioides difficile Infection
AstraZeneca AB
Bacterial Infections and Mycoses
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
16/02/2026
Phase III
Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms. (OPIDYS-ALS).
2025-522546-52-00patients with chronic respiratory insufficiency due to amyo…
DrugMorphine
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
13/02/2026
Phase III
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
2025-523533-25-00Cancer-associated Cachexia
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase I/II
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posi…
Amgen Inc.
Neoplasms
France, Netherlands, Italy
13/02/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
2025-522279-27-00Newly Diagnosed AML with an NPM1 mutation
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase III
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
2025-523275-27-00Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyri…
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Italy, France, Ireland, Belgium, Sweden, Germany, Netherlands, Norway, Spain
12/02/2026
Phase III
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00Metastatic colorectal cancer
Summit Therapeutics Inc.
Neoplasms
Belgium, Italy, Spain, Germany, France, Poland, Czechia, Hungary
12/02/2026
Phase III
A Long-term Extension Study of the Safety and Efficacy of Cleminorexton in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored Cleminorexton Clinical Trial
2025-522987-34-00Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals UK Limited
Nervous System Diseases
France, Spain, Italy
12/02/2026
Phase III
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction (SEVENAZA)
2025-521634-29-00ONCOLOGY, Acute Myeloid Leukemia
Institut Gustave Roussy
Immune System Diseases
France, Spain
11/02/2026
Phase III
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR]
2025-522193-37-00Septic arthritis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
10/02/2026
Phase I
A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a personalized immunotherapy, in patients with metastatic or locally advanced colon cancer of pancreatic cancer
2025-523172-23-00Metastatic or locally advanced pancreatic cancer, Metastati…
Centr Georges Francois Leclerc
Digestive System Diseases
France
10/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.
2025-523231-19-00Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.
Neoplasms
Italy, Germany, Greece, Spain, Austria, France, Netherlands
10/02/2026
Phase III
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
2024-519504-27-00Relapsed Refractory Multiple Myeloma
DrugsDiphenhydramine hydrochloride·Linvoseltamab·Paracetamol·Velcade
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.
2025-523230-77-00Patients with locally advanced Basal Cell Carcinoma (LaBCC)…
Philogen S.p.A.
Neoplasms
Germany, Italy, Greece, Spain, France
10/02/2026
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
2025-522703-14-00"Moderate to severe obstructive sleep apnea (OSA) in adults…
Amgen Inc.
Respiratory Tract Diseases
Poland, Germany, Czechia, Hungary, Spain, France
10/02/2026
Phase III
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2025-520805-10-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
DrugEmpasiprubart
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase II
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)
2025-520993-20-00Generalized Myasthenia Gravis
DrugInebilizumab
Amgen Inc.
Nervous System Diseases
Spain, Italy, Poland, France
09/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy
2025-523213-29-00X-linked myotubular myopathy
Astellas Gene Therapies Inc.
Musculoskeletal Diseases
France
09/02/2026
Phase I
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor
2025-522033-64-00Myelofibrosis
Ajax Therapeutics Inc.
Neoplasms
Italy, France, Spain
09/02/2026
Phase I
A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC
2025-522543-18-00Advanced Clear Cell Renal Cell Carcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France
09/02/2026
Phase I
A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults.
2025-522652-58-01Narcolepsy
H. Lundbeck A/S
Nervous System Diseases
France
09/02/2026
Phase IV
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
2025-521621-33-00Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Ad…
Replimune Group Inc.
Neoplasms
Germany, Greece, France, Poland, Spain
09/02/2026
Phase III
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination with Osimertinib, Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
2025-521124-29-00Non-Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Italy, Spain, Poland, Netherlands, Germany, Belgium, Austria, France
09/02/2026
Phase III
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE
2025-521142-22-00Hereditary Angioedema
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
2025-521038-27-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis.
2025-521035-37-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)
2025-521742-15-00Treatment of Late Isolated Microvascular Inflammation in Re…
Biogen Idec Research Limited
Immune System Diseases
Germany, Austria, Spain, Czechia, France
09/02/2026
Phase II
A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
2025-522892-27-00Bronchiectasis
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase I/II
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
2024-519881-32-00Sickle Cell Disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France
06/02/2026
Phase II
A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE
2025-524199-40-00neurology
Hospices Civils De Lyon
Nervous System Diseases
France
06/02/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
2025-522229-37-00Gastrointestinal Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany
06/02/2026
Phase IV
Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohn’s Disease : EMINENT CD
2025-521889-95-00Crohn's Disease
Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif
Digestive System Diseases
France
05/02/2026
Phase I
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor
2025-524385-18-00Non-alcoholic steatohepatitis
Inventiva
Digestive System Diseases
France
04/02/2026
Phase I
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
2025-521394-13-00Relapsed/refractory Acute Myeloid Leukemia or relapsed/refr…
Auron Therapeutics Inc.
Neoplasms
France
04/02/2026
Phase II
An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy
2025-521642-14-00Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
Nervous System Diseases
France, Germany, Italy, Spain
04/02/2026
Phase II
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease
2025-521966-91-00Refractory Metastatic Breast Cancer with Liver Dominant Dis…
Delcath Systems Inc.
Neoplasms
Italy, Spain, Sweden, France, Germany
04/02/2026
Phase III
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
2025-522015-42-00Chronic Hepatitis D Infection
Mirum Pharmaceuticals Inc.
Virus Diseases
Czechia, Austria, Spain, Romania, Germany, Italy, France
03/02/2026
Phase I/II
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04–Substudy 04D
2025-522253-19-00Urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, France, Spain
03/02/2026
Phase III
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
2025-522960-34-00Hypertension, Established cardiovascular disease, High card…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
2025-523349-86-00Acute Myocardial Infarction
DrugsMethoxyflurane·Morphine
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
02/02/2026
Phase III
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients ≥75 years old
2025-521619-37-00Patients ≥75 years old with cT3/T4 rectal adenocarcinoma el…
DrugsCalcium levofolinate·Folinic acid·Fluorouracil·Oxaliplatin
Unicancer
Neoplasms
France
02/02/2026
Phase I
A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC
2025-522914-22-00Locally Advanced Head and Neck Squamous Cell Carcinoma (LA …
Janssen Cilag International
Neoplasms
France, Spain
02/02/2026
Phase II
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
2025-521560-36-00Type 1 Diabetes
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase III
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
2025-522387-32-00Uveal Melanoma
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany
29/01/2026
Phase II
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
2025-522533-54-00Metastatic Non-small cell lung cancer (NSCLC) and Pancreati…
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase III
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00Patients with primary HPV high-grade squamous intra-epithel…
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase II
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
2025-521636-10-00Progressive Forms of Multiple Sclerosis (PMS)
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Spain, France, Hungary, Italy, Poland, Portugal
28/01/2026
Phase III
A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)
2025-522699-94-00Moderate to severe obstructive sleep apnea (OSA) in adults …
Amgen Inc.
Respiratory Tract Diseases
Poland, Czechia, Germany, Hungary, France, Spain
27/01/2026
Phase III
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)
2025-522792-29-00Alpha-1 Antitrypsin Deficiency
DrugIVIG
Grifols Therapeutics LLC
Respiratory Tract Diseases
Poland, Denmark, Netherlands, Ireland, Sweden, Spain, Portugal, Germany, France
27/01/2026
Phase III
N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
2025-522674-36-00Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521558-40-00Pulmonary Hypertension Associated with Interstitial Lung Di…
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase I/II
Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer
2025-523286-23-00Breast Cancer
Centre Henri Becquerel
Not possible to specify
France
26/01/2026
Phase III
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial
2025-521805-41-00Patients with HER2-positive, locally advanced or metastatic…
DrugsPertuzumab·Trastuzumab deruxtecan
Solti Group
Neoplasms
France, Germany, Spain
26/01/2026
Phase III
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia
2024-519068-42-00​Heterozygous Familial Hypercholesterolemia​ in pediatric p…
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase II
SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
2024-516558-24-00Pancreatic (PAAD)
Centre Leon Berard
Neoplasms
France
23/01/2026
Phase III
CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvid® and Tauvid®) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.
2025-523264-21-00Semantic Variant Primary Progressive Aphasia, Alcohol Use D…
Institut National De La Sante Et De La Recherche Medicale
Mental Disorders
France
23/01/2026
Phase II
Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
2025-522556-10-01Ocular Sequelae in Lyell syndrome
DrugTildrakizumab
TOXILYON
Eye Diseases
France
23/01/2026
Phase II
Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)
2025-522012-16-00Breast Cancer
Alx Oncology Holdings Inc.
Neoplasms
Spain, Italy, France
23/01/2026
Phase III
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
2025-521792-31-01Homozygous Familial Hypercholesterolemia (HoFH)
DrugZodasiran
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase II
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study)
2025-521918-26-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Spain, Belgium, France, Germany, Italy, Portugal, Poland
23/01/2026
Phase I
An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus authorized SARS-CoV-2 vaccine candidates as a booster dose in healthy participants previously vaccinated with authorized mRNA SARS-CoV-2 vaccines.
2025-520652-28-00healthy participants
ANRS Maladies Infectieuses Emergentes
Pathological Conditions, Signs and Symptoms
France
21/01/2026
Phase II
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study
2025-522743-18-00Gambling disorder
DrugPsilocybin
Centre Hospitalier Universitaire De Nantes
Behavior and Behavior Mechanisms
France
21/01/2026
Phase II
J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00Asthma
Eli Lilly & Co.
Respiratory Tract Diseases
Germany, Netherlands, France, Poland
21/01/2026
Phase I/II
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
2025-521973-16-00Netherton Syndrome
Biocryst Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
France, Netherlands, Germany
20/01/2026
Phase III
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
2025-521284-12-00Non-small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
2025-521908-22-00EGFR-mutated Non-small Cell Lung Cancer
DrugsPegfilgrastim·Iza-bren·Pemetrexed·Cisplatin
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Germany, Italy, Norway, Netherlands, Belgium, Romania, France, Greece, Spain
19/01/2026
Phase II
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
2025-521606-18-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Czechia, France, Belgium, Denmark
19/01/2026
Phase III
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)
2023-503766-24-00Moderate to Severe Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase I/II
DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional βAS3m/miR7m lentiviral vector expressing the βAS3m and a micro-RNA (miRNA) targeting specifically the endogenous βS-globin mRNA in Patients with Sickle Cell Disease (SCD)
2025-521257-17-00SCD severe patients
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
16/01/2026
Phase I/II
A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer
2025-523273-41-00Metastatic castration-resistant prostate cancer
T.O.A.D. Oncology S.A.
Neoplasms
Spain, France
16/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00BP-I mania or mania with mixed features
DrugKarXT
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025-521917-24-00Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous…
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase II
A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
2025-521503-43-00Atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
France, Germany, Poland, Czechia, Bulgaria
14/01/2026
Phase I
A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)
2025-522398-12-00Locally advanced or metastatic NSCLC
Astellas Pharma Global Development Inc.
Neoplasms
France, Spain
14/01/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.
2024-520353-21-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Norway, Germany, France, Italy
14/01/2026
Phase I/II
A Phase 1/2, multicentre, open-label clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected advanced solid tumours
2025-523758-15-00Cancer
Domain Therapeutics Australia Pty Limited
Neoplasms
France
14/01/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
2025-521514-26-00Persistent, Recurrent, or Newly Diagnosed Metastatic Cervic…
Merck Sharp & Dohme LLC
Neoplasms
Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy
14/01/2026
Phase II
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)
2025-522232-13-00Sepsis-associated acute kidney injury (AKI)
DrugAZD4144
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase III
A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT)
2023-510075-63-00Patients with ventilator-associated tracheobronchitis
Centre Hospitalier Regional Universitaire De Tours
Bacterial Infections and Mycoses
France
12/01/2026
Phase III
A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors
2025-521043-20-00Neuroendocrine tumors
Exelixis Inc.
Neoplasms
France, Poland, Netherlands, Belgium, Germany, Spain, Italy, Austria
09/01/2026
Phase II
Efficacy and safety of Remimazolam compared to Ketamine and Propofol in Rapid Sequence Induction. A monocentric pilot randomised-controlled study
2025-521602-18-00Rapid Sequence Induction in operating room
DrugsRemimazolam·Ketamine·Propofol
Centre Hospitalier Universitaire De Nantes
Anesthesia and Analgesia
France
06/01/2026
Phase IV
DOSABEMA-Pharmacokinetic model of abemaciclib: correlation with severe diarrhea as the primary toxicity endpoint in patients with hormone receptor-positive localized breast cancer
2025-521696-31-00HR+, HER2- breast cancer at high risk of recurrence
DrugAbemaciclib
Centre Hospitalier Universitaire De Poitiers
Neoplasms
France
06/01/2026
Phase III
A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)
2025-523690-41-00Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca AB
Respiratory Tract Diseases
France
24/12/2025
Phase III
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
2023-508784-68-00metastatic uveal melanoma
DrugsRP2·Ipilimumab·Nivolumab
Replimune Inc.
Neoplasms
Germany, Italy, France, Spain, Poland
23/12/2025
Phase I/II
An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants with Locally Advanced or Metastatic Solid Tumours.
2025-522139-33-00Advanced or metastatic solid tumours
Ipsen Pharma
Neoplasms
France, Spain
23/12/2025
Phase II
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
2025-520675-86-00Unresectable or Metastatic Hepatocellular Carcinoma and Com…
CatalYm GmbH
Neoplasms
Germany, France, Italy, Spain
23/12/2025
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease
2025-522683-32-00Early-Stage Parkinson’s Disease (PD)
F. Hoffmann-La Roche AG
Nervous System Diseases
France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy
23/12/2025
Phase II
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa
2025-522333-61-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Poland, Hungary, Netherlands, Germany, Czechia, Spain, France, Italy, Greece
22/12/2025
Phase IV
TRAMORNOT: Tramadol versus morphine in postoperative analgesia after laparoscopic abdominal surgery: a randomized controlled trial
2025-523327-21-00Postoperative pain following scheduled major laparoscopic a…
DrugsTramadol·Morphine
Centre Hospitalier Universitaire Amiens Picardie
Anesthesia and Analgesia
France
22/12/2025
Phase III
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
2025-521117-88-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
France, Denmark, Germany, Spain, Italy, Netherlands
22/12/2025
Phase III
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
2024-515765-34-00English First-line extensive-stage small-cell lung cancer (…
BioNTech SE
Neoplasms
Poland, Spain, France, Italy, Germany, Romania, Netherlands
22/12/2025
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…
DrugMK-3120
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase III
C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase II
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.
2025-522309-40-00Non-segmental vitiligo
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
Poland, Italy, Spain, France
19/12/2025
Phase I
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants.
2025-523587-20-00Not applicable for phase I study
Gruenenthal GmbH
Not possible to specify
France
19/12/2025
Phase III
IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
2025-522400-24-00Metastatic urothelial cancer
Bristol-Myers Squibb Services Unlimited Company
Female Urogenital Diseases and Pregnancy Complications
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase III
A Phase III, randomised, double-blind, placebo-controlled, parallel-group, pivotal trial to assess the efficacy and safety of sonlicromanol in adult subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G variant.
2025-522361-30-00Primary Mitochondrial Disease, Mitochondrial DNA 3243A>G va…
DrugSonlicromanol
Khondrion B.V.
Nervous System Diseases
Italy, Germany, France, Netherlands, Denmark
19/12/2025
Phase III
A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)
2025-522996-27-00recurrent and/or metastatic squamous cell carcinoma of the …
DrugsLigufalimab·Ivonescimab·Pembrolizumab
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France, Spain, Belgium
18/12/2025
Phase I/II
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
2025-521873-15-00Metastatic hormone-sensitive prostate cancer
Novartis Pharma AG
Neoplasms
Hungary, Spain, Italy, Germany, France
18/12/2025
Phase IV
Evaluation of postoperative recovery when combining intravenous lidocaine with ropivacaine infiltration in laparoscopic colorectal oncologic surgery: a randomized controlled trial
2025-523207-29-00colorectal cancer laparoscopic surgery
Centre Hospitalier Universitaire Amiens Picardie
Not possible to specify
France
17/12/2025
Phase III
C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
2025-522093-36-00Cancer cachexia
Pfizer Inc.
Nutritional and Metabolic Diseases
Slovakia, Italy, Belgium, Germany, Spain, France, Bulgaria, Poland
16/12/2025
Phase III
Effects of butyrate enemas on postoperative intestinal motility disorders in Hirschsprung’s disease
2025-523094-42-00Hirschsprung's disease
Assistance Publique Hopitaux De Marseille
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
16/12/2025
Phase I/II
An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
2025-522184-15-00Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen Pharma
Neoplasms
Spain, France
16/12/2025
Phase II
Is [18F]-DPA-714 PET a good marker of neuroinflammation in autoimmune encephalitis? (EAI-714)
2025-522768-33-00autoimmune encephalitis
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
15/12/2025
Phase III
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease
2025-521113-13-00Early Parkinson’s Disease
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase III
Intermediate versus standard dose enoxaparin to prevent venous thromboembolism in severe trauma patients: a multicenter double blind randomised controlled trial (HEPTRAUMA)
2025-522832-16-00Severe trauma
Centre Hospitalier Universitaire Grenoble Alpes
Hemic and Lymphatic Diseases
France
11/12/2025
Phase III
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
2024-519444-33-00HER2-expressing endometrial cancer (IHC 3+/2+)
Daiichi Sankyo Inc.
Neoplasms
Germany, Poland, France, Greece, Spain, Portugal, Italy
11/12/2025
Phase II
A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome
2024-519393-39-00Angelman Syndrome
Ultragenyx Pharmaceutical Inc.
Nervous System Diseases
Portugal, Italy, France
11/12/2025
Phase I
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors
2025-523165-19-00Advanced, metastatic or unresectable solid tumors
BeOne Medicines I GmbH
Neoplasms
Denmark, France
11/12/2025
Phase III
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
2025-522151-26-00Advanced or Metastatic Non-Small-Cell Lung Cancer With Epid…
Arrivent Biopharma Inc.
Neoplasms
Greece, France, Spain, Italy
10/12/2025
Phase III
AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00Philadelphia Chromosome Positive or ABL-class Philadelphia …
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase II
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)
2024-519788-16-00Adult patients with histologically/cytologically confirmed …
Institut Gustave Roussy
Neoplasms
France
09/12/2025
Phase II
SYMBOL CLINICAL : Treatment of severe ocular chemical burns by subconjunctival injection of allogeneic mesenchymal stem cells: a multicentre, single-arm, open-label phase II trial
2023-509713-37-00Patient with severe eye chemical burns
DrugsRemifentanil·Paracetamol·Midazolam·Propofol
Hopital Fondation Adolphe De Rothschild
Eye Diseases
France
09/12/2025
Phase III
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term Extension
2024-519578-38-00Classic congenital adrenal hyperplasia
Crinetics Pharmaceuticals Inc.
Hormonal diseases
Italy, Germany, France, Belgium, Netherlands, Poland
09/12/2025
Phase III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia
09/12/2025
Phase III
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
2023-509392-17-00Relapsed Acute Lymphoblastic Leukemia (ALL)
DrugsIdarubicin·Inotuzumab Ozogamicin·Pegaspargase·Mercaptopurine
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Slovenia
09/12/2025
Phase II
An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.
2025-521852-45-00Cutaneous T-Cell Lymphoma
Prescient Therapeutics Limited
Neoplasms
Italy, France
08/12/2025
Phase III
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
2024-512804-20-00Metastatic Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, France, Italy, Netherlands, Spain
08/12/2025
Phase II
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
2024-518231-11-00Immune thrombocytopenia (ITP) Warm autoimmune hemolytic an…
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase II
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
2024-516471-33-00Alport Syndrome, Chronic kidney disease
Bayer AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, Poland, Czechia, Germany, Portugal, France
05/12/2025
Phase II
A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis
2024-517980-22-00Multiple Sclerosis (MS)
F. Hoffmann-La Roche AG
Immune System Diseases
Poland, Italy, France, Spain, Germany
05/12/2025
Phase III
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
2024-512486-14-00Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase II
A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
2025-522074-37-00Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertensi…
Allrock Bio Inc.
Cardiovascular Diseases
Spain, Italy, Poland, France, Latvia, Germany
04/12/2025
Phase I
First-in-Human trial of DS9051b in participants with advanced solid tumors
2025-521886-28-00Advanced or Metastatic Adrenocortical Carcinoma (ACC), Meta…
Daiichi Sankyo Inc.
Neoplasms
France
03/12/2025
Phase III
Fecal microbiota transplantation for primary sclerosing cholangitis - randomized study versus sham transplantation (FMT-SCLER).
2023-505469-95-00Primary Sclerosing Cholangitis
Assistance Publique Hopitaux De Paris
Nutritional and Metabolic Diseases
France
02/12/2025
Phase IV
Impact of influenza vaccination on nasal resident memory immune responses and respiratory peripheral memory immune responses - MUCOVAC 2
2025-521217-46-00Adults seeking active immunisation against the seasonal inf…
Centre Hospitalier Universitaire De Saint Etienne
Virus Diseases
France
02/12/2025
Phase II
A dose-ranging randomized, open-label study evaluating the effect of bilateral intravitreal injection of GS010 at two dose levels on visual acuity and retinal mitochondrial activity in patients affected with ND4 Leber Hereditary Optic Neuropathy – The REVISE Study
2025-523339-20-00Leber Hereditary Optic Neuropathy due to mutations in the m…
Gensight Biologics
Eye Diseases
France
02/12/2025
Phase III
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
2024-512298-28-00Neovascular age-related macular degeneration
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase III
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia
2024-519579-24-00Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Hormonal diseases
Sweden, Austria, Poland, Netherlands, Italy, France, Germany
02/12/2025
Phase II
C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
2025-521155-23-00Pulmonary Arterial Hypertension
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
2024-520337-80-00Palmoplantar Pustulosis
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
2025-521382-27-00Moderately to Severely Active Crohn's Disease
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
2025-521381-10-00Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
Digestive System Diseases
Netherlands, Romania, Italy, Spain, Sweden, Czechia, Greece, Hungary, France, Portugal, Belgium, Germany, Poland
01/12/2025
Phase I/II
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Italy, Germany, Poland, France, Denmark, Spain
01/12/2025
Phase III
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
2025-521970-33-00​​Pulmonary Arterial Hypertension (PAH)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2024-520097-36-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
DrugEmpasiprubart
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase II
A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
2025-522146-40-00Late-onset Pompe disease.
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase II
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Inc.
Genetic Phenomena
France, Germany, Italy, Belgium, Spain, Netherlands
28/11/2025
Phase I
A study to find a suitable dose of ASP5834 in adults with solid tumors
2025-522082-29-00Locally advanced (unresectable) or metastatic solid tumor m…
Astellas Pharma Inc.
Neoplasms
Spain, France
28/11/2025
Phase III
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
2025-522598-12-00Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase III
Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement: a randomized, placebo-controlled, double-blinded multicenter superiority study
2024-519620-24-01ANCA-associated vasculitis
Centre Hospitalier Universitaire De Toulouse
Immune System Diseases
France
27/11/2025
Phase II
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2025-520730-28-00Common EGFR-Mutated Locally Advanced or Metastatic Non-Smal…
Janssen Cilag International
Neoplasms
Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France
27/11/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
2024-514500-14-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Germany, Italy, France, Poland, Spain, Hungary, Romania, Greece, Austria, Netherlands, Belgium
27/11/2025
Phase IV
Erector Spinae Plane Block for acute low back pain: a prospective double-blind randomized multicenter study. ESP-BACK
2024-511595-32-00Acute low back pain
DrugsKetoprofen·Tramadol·Paracetamol·Ropivacaine
Centre Hospitalier Universitaire De Montpellier
Anesthesia and Analgesia
France
26/11/2025
Phase I/II
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
2025-522510-23-00Hereditary Hemorrhagic Telangiectasia (HHT)
Alnylam Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Germany
26/11/2025
Phase I
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
2023-509729-33-00Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory
Institut De Cancerologie De L Ouest
Neoplasms
France
26/11/2025
Phase III
A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of Glepaglutide in adult patients with short bowel syndrome (SBS) rolling over from the EASE SBS 2 or 3 trials
2025-520775-81-00Short Bowel Syndrome
Zealand Pharma A/S
Digestive System Diseases
Poland, France, Germany, Belgium
26/11/2025
Phase II
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
2025-522054-40-00Previously treated advanced melanoma
Iovance Biotherapeutics Inc.
Skin and Connective Tissue Diseases
France, Italy, Germany, Spain
26/11/2025
Phase I/II
A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor
2025-521128-31-00Locally Advanced or Metastatic Estrogen Receptor-Positive, …
DrugsRGT-419B·Giredestrant·Abemaciclib
Genentech Inc.
Neoplasms
Spain, Italy, France, Germany
26/11/2025
Phase III
Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
2024-513911-28-00Acute Ischemic Stroke
Diamedica Therapeutics Inc.
Nervous System Diseases
Romania, Hungary, Belgium, Poland, Spain, France
25/11/2025
Phase I
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
2024-518780-36-00Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
Musculoskeletal Diseases
Bulgaria, Romania, France, Germany, Spain, Poland
25/11/2025
Phase III
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
2023-508071-36-00Patients hospitalised in intensive care, diagnosed with sep…
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase II
BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
2024-514848-88-00Folliculitis decalvans
DrugsUstekinumab·Baricitinib·Adalimumab
Assistance Publique Hopitaux De Paris
Therapeutics
France
24/11/2025
Phase IV
Comparison of morphine and alfentanil in the emergency treatment of severe acute pain in the pre-hospital setting
2025-522817-50-00Severe pain
DrugsAlfentanil·Morphine
CHU De Martinique
Population Characteristics
France
24/11/2025
Phase II
PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
2025-521371-31-00Sepsis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
24/11/2025
Phase III
Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
2024-515023-11-00Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear …
DrugsCasdatifan·Cabozantinib
Arcus Biosciences Inc.
Neoplasms
Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary
24/11/2025
Phase III
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.
2024-520418-22-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase II
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
2025-521034-28-00Moderate to Severe Rheumatoid Arthritis (RA)
DrugAfimkibart
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase I
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.
2025-521407-52-00Advanced Solid Tumors
Janssen Cilag International
Neoplasms
France
21/11/2025
Phase I/II
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
2025-521672-60-00Metastatic or locally advanced SST2-positive neuroendocrine…
Crinetics Pharmaceuticals Inc.
Neoplasms
Spain, France, Germany, Italy
21/11/2025
Phase III
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00Macular neovascularization secondary to age-related macular…
4d Molecular Therapeutics Inc.
Eye Diseases
Germany, Italy, Hungary, Bulgaria, Lithuania, France, Spain, Latvia, Portugal
21/11/2025
Phase II
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)
2025-520780-40-00Primary Mebranous Nephropathy (PMN)
Alexion Pharmaceuticals Inc.
Immune System Diseases
Spain, France, Italy
20/11/2025
Phase II
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy
Imbria Pharmaceuticals Inc.
Cardiovascular Diseases
Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland
20/11/2025
Phase I/II
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
2025-521828-30-00Advanced Solid Tumors
Pyxis Oncology Inc.
Neoplasms
France, Spain, Poland
19/11/2025
Phase III
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
2025-522860-34-00Small lymphocytic lymphoma (SLL), Chronic lymphocytic leuke…
BeOne Medicines AG
Neoplasms
Sweden, Belgium, Spain, Germany, Austria, Netherlands, Italy, Romania, Poland, France
18/11/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
2025-520927-26-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
France, Belgium, Spain, Poland, Italy, Netherlands, Germany
18/11/2025
Phase II
Phase 2, Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Tarperprumig in Adult Participants with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
2025-521706-17-00Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasc…
Alexion Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, France, Italy, Germany, Poland
17/11/2025
Phase II
FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
2025-521322-14-00Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1…
DrugsIvosidenib·Azacitidine
French Innovative Leukemia Organization
Hemic and Lymphatic Diseases
France
17/11/2025
Phase II
ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders
2025-522841-23-00Autism Spectrum disorder ASD
Assistance Publique Hopitaux De Paris
Mental Disorders
France
17/11/2025
Phase III
C5851005 - PADLINK-005: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)
2025-521281-97-00Non-Small Cell Lung Cancer (NSCLC)
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
NoLEEta - No chemotherapy in intermediate-risk HR+ HER2- early breast cancer treated with Ribociclib (LEE-011) in the adjuvant setting, a noninferiority Phase III trial
2025-520979-13-00Patients with HR+ HER2- early breast cancer at intermediate…
Unicancer
Neoplasms
Germany, Spain, Netherlands, France, Italy
17/11/2025
Phase III
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
2024-518777-34-00B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
DrugsDoxorubicin·Paclitaxel
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
DrugsTreosulfan·Thiotepa·Busulfan·Blinatumomab
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia
17/11/2025
Phase II
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE 2B TRIAL TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0217 FOR 24 WEEKS IN ADULTS AND OLDER ADOLESCENTS WITH DOWN SYNDROME
2025-521013-10-00Treatment of behavioural and cognitive impairments in Down …
Aelis Farma
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, France
17/11/2025
Phase III
LEISURE : Lenalidomide vs methotrexate in difficult-to-treat cutaneous lupus erythematosus (LEISURE trial): An assessor-blinded randomized clinical trial
2024-520089-70-00Cutaneous lupus erythematosus
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
France
14/11/2025
Phase II
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)
2024-517711-70-01Narcolepsy without Cataplexy (NT2)
Takeda Development Center Americas Inc.
Nervous System Diseases
Spain, Italy, France
14/11/2025
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Atopic Dermatitis who Participated in Previous Afimkibart Clinical Trials
2025-520771-59-00Atopic Dermatitis
F. Hoffmann-La Roche AG
Skin and Connective Tissue Diseases
Italy, Poland, Germany, Spain, France
13/11/2025
Phase II
A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206)
2024-516551-41-00Patients with HER2-expressing solid tumors
Jazz Pharmaceuticals Ireland Limited
Neoplasms
Spain, France, Italy
13/11/2025
Phase II
A DOSE-DETERMINATION STUDY OF SUGAMMADEX AS A ROCURONIUM DECURARIZATION AGENT IN CHILDREN UNDER 2 YEARS OF AGE
2025-521946-82-00Non-urgent non-cardiac surgical procedure or relative emerg…
Centre Hospitalier Universitaire De Caen Normandie
Anesthesia and Analgesia
France
12/11/2025
Phase II
BRECHE : Efficacy of sphenopalatine block compared to blood patch in the management of post-dural puncture syndrome.
2025-522168-34-00Post-dural puncture syndrome
University Hospital Of Clermont-Ferrand
Therapeutics
France
12/11/2025
Phase II
MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA
2024-514399-42-00Glioblastoma
DrugsUCPVax·Temozolomide·Pembrolizumab
Centre Hospitalier Regional Universitaire
Immune System Diseases
France
12/11/2025
Phase III
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
2024-513586-39-00Prostate Cancer
AstraZeneca AB
Male Urogenital Diseases
Austria, Sweden, Spain, France, Netherlands, Germany, Belgium, Finland, Hungary, Poland, Italy
12/11/2025
Phase I/II
A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors
2025-521441-24-00Advanced or Metastatic Solid Tumors
Alentis Therapeutics AG
Neoplasms
Spain, France, Netherlands, Italy
12/11/2025
Phase II
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
2025-521737-91-00Neoplasm malignant with KRAS G12C mutation
Merck Sharp & Dohme LLC
Neoplasms
Norway, Spain, Sweden, Italy, Denmark, France, Poland, Germany, Greece
12/11/2025
Phase I/II
A Phase I/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, and pharmacokinetics of BNT323 in combination with BNT327 in participants with advanced breast cancer
2024-517979-20-00Advanced Breast Cancer Metastatic Breast Cancer
BioNTech SE
Neoplasms
Italy, Spain, France
11/11/2025
Phase III
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
2025-523083-21-00PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Gr…
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase III
ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiotic strategy applied to patients with asymptomatic bacteriuria undergoing intra-vesical botulinum toxin A injections
2024-515107-19-00Patients (male or female) ≥18 years old with Detrusor overa…
DrugAztreonam
Centre Hospitalier Universitaire De Lille
Nervous System Diseases
France
10/11/2025
Phase II
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
2025-521242-26-00Moderately to Severely Active Ulcerative Colitis
DrugsSPYPBO-101·SPY001·SPY002·SPY003
Spyre Therapeutics Inc.
Digestive System Diseases
Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia
10/11/2025
Phase III
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)
2024-517136-21-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase II
A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 in Adult Participants with Moderate or Severe Asthma (the POLARIS trial)
2025-521391-58-00Asthma
Windward Bio AG
Respiratory Tract Diseases
Germany, France, Sweden, Bulgaria, Spain
10/11/2025
Phase III
A Phase 3, Multi-center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2025-522862-58-00Locally advanced unresectable or metastatic gastric or gast…
BeOne Medicines AG
Neoplasms
Spain, France, Austria, Italy, Poland, Czechia
10/11/2025
Phase II
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
2024-519511-33-00Patients will be included with a stable but active disease …
Centre Hospitalier Universitaire De Montpellier
Immune System Diseases
France
07/11/2025
Phase III
A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY Kids)
2024-512577-27-00Chronic kidney disease in paediatric patients
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Spain, Germany, Portugal, Netherlands, Belgium, Poland, Italy, France, Sweden, Hungary
06/11/2025
Phase II
IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients
2024-519208-29-00Pleural mesothelioma
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
06/11/2025
Phase II
Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously untreated symptomatic chronic lymphocytic leukemia (CLL). A phase II FILO trial
2025-521199-80-00Patients with previously untreated symptomatic chronic lymp…
DrugPirtobrutinib
French Innovative Leukemia Organization
Hemic and Lymphatic Diseases
France
05/11/2025
Phase II
An Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)
2025-521904-23-00Locally Advanced Inoperable or Metastatic Breast Cancer Ref…
AstraZeneca AB
Neoplasms
Spain, France, Italy
05/11/2025
Phase III
Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease
2024-518437-28-00Sickle cell disease
Centre Hospitalier Universitaire De Nantes
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
05/11/2025
Phase III
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia
2025-521692-31-00Chronic Primary Immune Thrombocytopenia
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Bulgaria, Spain, Netherlands, Italy, Poland, Greece, Germany, France, Czechia, Croatia, Norway, Sweden
04/11/2025
Phase II
Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)
2025-521567-12-00Vernal Keratoconjunctivitis (VKC)
DrugCiclosporin
Laboratoires Thea
Eye Diseases
Spain, Italy, Bulgaria, France, Greece
04/11/2025
Phase III
EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)
2024-519404-27-00​​IDH-mutant grade 2 or 3 astrocytoma​
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
Neoplasms
Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium
04/11/2025
Phase III
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.
2025-522395-92-00metastatic oeso-gastric adenocarcinoma
Fondation Franc.Cancerologie Digestive
Neoplasms
France, Germany, Spain
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
2024-518008-33-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
F. Hoffmann-La Roche AG
Nervous System Diseases
Poland, France, Germany, Netherlands, Spain, Italy, Denmark
04/11/2025
Phase III
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)
2024-518006-40-00Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia…
DrugsFlorbetaben·Trontinemab
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Poland, Italy, Denmark, France, Germany
04/11/2025
Phase III
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
2025-521012-18-00Facioscapulohumeral Muscular Dystrophy (FSHD)
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, France, Germany, Spain, Denmark, Netherlands
04/11/2025
Phase II
A Seamless Phase 2a/2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
2025-521293-34-00Moderate-to-severe hidradenitis suppurativa
DrugAdalimumab
Almirall S.A.
Skin and Connective Tissue Diseases
Germany, Italy, Ireland, Poland, Spain, France
03/11/2025
Phase I/II
A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and expansion study of GSK5458514 PSMA targeting T cell engager alone or in combination with other anti-cancer agents in adult participants with metastatic castration-resistant prostate cancer (mCRPC)
2025-521581-10-00Neoplasms, Prostate
Glaxosmithkline Research & Development Limited
Neoplasms
France, Spain
03/11/2025
Phase I/II
A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
2025-522517-35-00Patients with advanced/metastatic tumors with head and neck…
Gilead Sciences Inc.
Neoplasms
France, Spain, Romania
03/11/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
2024-519493-39-00High-risk Non-muscle-invasive Bladder Cancer with Susceptib…
Janssen Cilag International
Neoplasms
France, Germany, Spain, Netherlands, Italy, Belgium, Greece
03/11/2025
Phase III
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia
2024-517238-16-00Hypochondroplasia
Biomarin Pharmaceutical Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Italy, Germany
03/11/2025
Phase III
A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria
2024-519554-37-00Phenylketonuria
Otsuka Pharmaceutical Development & Commercialization Inc.
Nervous System Diseases
Czechia, Italy, Spain, Netherlands, Poland, France, Germany
03/11/2025
Phase III
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
2025-521711-39-00Lewy body Dementia psychosis (LBDP)
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Italy, France, Bulgaria
03/11/2025
Phase III
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00Metastatic castration-resistant prostate cancer (mCRPC)
Amgen Inc.
Neoplasms
Austria, Netherlands, Portugal, Spain, Belgium, Greece, France, Italy, Germany
03/11/2025
Phase II
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of Age and Older With Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization
2025-523009-14-00Bronchiectasis with chronic pseudomonas aeruginosa coloniza…
AstraZeneca AB
Respiratory Tract Diseases
Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany
31/10/2025
Phase I
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.
2024-516625-31-00Advanced Solid Tumor
Daiichi Sankyo Inc.
Neoplasms
Spain, France
30/10/2025
Phase III
Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial
2025-521317-50-00Cholestatic hepatitis induced by immune checkpoint inhibito…
Centre Hospitalier Universitaire De Montpellier
Digestive System Diseases
France
30/10/2025
Phase III
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial
2025-521039-35-00Impact on delirium of the use of DEXmedetomidine as first-…
DrugsMidazolam·Dexmedetomidine
Centre Hospitalier Regional Universitaire De Tours
Anesthesia and Analgesia
France
29/10/2025
Phase II
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)
2025-521710-25-00Lewy Body Dementia Psychosis (LBDP)
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Bulgaria, Czechia, Italy, France
29/10/2025
Phase II
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
2025-521144-38-00Primary Central Nervous System Lymphoma
Bristol-Myers Squibb Services Unlimited Company
Nervous System Diseases
France, Germany
29/10/2025
Phase II
NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma
2025-522127-95-00NEOREM: Localized solid malignancies that are eligible to r…
Unicancer
Neoplasms
France
28/10/2025
Phase II
An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease
2024-520208-25-00Still’s disease
Novartis Pharma AG
Immune System Diseases
Italy, Netherlands, Spain, France, Germany
28/10/2025
Phase I
European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.
2023-504282-23-00Faecal incontinence
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2024-519820-26-00Hallucinations and Delusions Associated with Alzheimer’s Di…
Maplight Therapeutics Inc.
Nervous System Diseases
France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland
27/10/2025
Phase III
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
2023-507525-42-00Endometrial cancer
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase I
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer
2025-521981-90-00Advanced Solid Tumors
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase III
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
2025-520731-17-02Pulmonary arterial hypertension (PAH)
DrugSotatercept
Centre Hospitalier Regional Et Universitaire De Brest
Diagnosis
France
24/10/2025
Phase II
BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
2024-520308-24-00Adult patients with persistent dyspnea more than 3 months a…
DrugBevacizumab
Assistance Publique Hopitaux De Paris
Virus Diseases
France
24/10/2025
Phase III
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.
2025-521511-40-00metastatic non-small cell lung cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain
24/10/2025
Phase III
A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease
2025-521398-15-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands, Spain, France, Belgium, Sweden, Germany, Poland, Italy
24/10/2025
Phase II
LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias
2024-520200-26-00Inherited anemias
Eurobloodnet Association
Hemic and Lymphatic Diseases
Italy, France
24/10/2025
Phase II
ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer
2025-521909-40-00Patients with metastatic or locally advanced HER2-low tripl…
Unicancer
Neoplasms
France
23/10/2025
Phase II
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor
2025-520468-16-00Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced U…
Genmab A/S
Neoplasms
France, Spain, Netherlands, Germany
23/10/2025
Phase II
A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.
2025-521107-42-00Alzheimer's Disease
Glaxosmithkline Research & Development Limited
Nervous System Diseases
Sweden, Norway, Italy, France, Spain, Finland, Netherlands, Germany
23/10/2025
Phase II
Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded controlled against placebo study
2024-517710-15-00thrombocytopenic patients undergoing cardiac surgery
Centre Hospitalier Universitaire De Nantes
Surgical Procedures, Operative
France
22/10/2025
Phase III
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
2024-513676-18-00Transthyretin Amyloidosis
DrugAcoramidis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Phase II
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer
2024-517653-27-00Prostate Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Italy, Poland, Spain, France, Germany
22/10/2025
Phase III
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521352-38-00Hereditary Angioedema
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-2)
2025-520612-34-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Poland, Hungary, Italy, France, Czechia
22/10/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
2024-514401-54-00Chronic Primary Immune Thrombocytopenia
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France
22/10/2025
Phase III
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
2025-521755-23-00Respiratory syncytial virus infection, Bronchiolitis, Respi…
Centre Hospitalier Annecy Genevois
Health Care Economics and Organizations
France
21/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)
2025-520746-30-00Mild to moderate Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Germany, Croatia, Italy, Poland, Romania, Czechia, Greece, Spain, France, Netherlands
21/10/2025
Phase III
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
2024-519994-20-00Agitation Associated with Alzheimer’s Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Croatia, Romania, France, Spain, Italy, Greece, Czechia, Bulgaria, Poland, Portugal, Hungary
21/10/2025
Phase II
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)
2024-520130-29-00Spinal Muscular Atrophy
Scholar Rock Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium, France, Italy, Spain, Netherlands
21/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
2025-520747-32-00Mild to moderate Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Germany, Netherlands, Portugal, France, Spain, Poland, Greece, Romania, Italy, Finland
21/10/2025
Phase III
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
2024-518365-10-00Previously Untreated Advanced or Metastatic Non-Squamous No…
F. Hoffmann-La Roche AG
Neoplasms
Ireland, Greece, Hungary, Netherlands, France, Denmark, Germany, Poland, Italy, Portugal, Spain, Belgium
21/10/2025
Phase II
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study
2024-520128-27-00colorectal adenocarcinoma
Association Gercor
Digestive System Diseases
France
20/10/2025
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months
2024-512261-14-00Hypochondroplasia
Biomarin Pharmaceutical Inc.
Genetic Phenomena
Germany, Italy, France
20/10/2025
Phase III
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
2025-521697-34-00Peanut allergy
Dbv Technologies
Immune System Diseases
Spain, France, Netherlands, Ireland
20/10/2025
Phase III
C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…
Pfizer Inc.
Neoplasms
Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy
20/10/2025
Phase III
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
2024-519976-19-00Asthma with type 2 inflammation characterized by an eosinop…
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Belgium, Spain, Italy, Greece, France, Germany
20/10/2025
Phase II
EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
2024-519960-42-00PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharma AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Netherlands, Belgium, Spain, Austria, Germany, France
20/10/2025
Phase II
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
2024-519753-11-00Resectable borderline pancreatic adenocarcinoma
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
17/10/2025
Phase III
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment
2024-519871-24-00Breast cancer, Triple-negative breast cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Portugal, Romania, Greece, Italy, Spain, Sweden, Austria, Poland, Germany
17/10/2025
Phase II
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
2024-519133-29-00Focal epilepsy
Fondation A De Rothschild
Nervous System Diseases
France
17/10/2025
Phase IV
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
2024-516232-10-00Serious infections in critically ill patients treated with …
Centre Hospitalier Universitaire De Nimes
Bacterial Infections and Mycoses
France
17/10/2025
Phase III
Efficacy of non operative treatment with amoxicillin/clavulanic acid versus surgical treatment in acute uncomplicated appendicitis in children: a prospective multicenter randomized controlled non-inferiority trial with cost utility analysis
2024-519402-12-00uncomplicated appendicitis
Centre Hospitalier Universitaire De Toulouse
Digestive System Diseases
France
17/10/2025
Phase III
SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss
2024-513710-35-00Patients presenting to ENT emergencies with a unilateral su…
Assistance Publique Hopitaux De Paris
Otorhinolaryngologic Diseases
France
17/10/2025
Phase II
Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study
2022-502362-24-00Erosive osteoarthritis
Centre Hospitalier Universitaire De Nice
Musculoskeletal Diseases
France
17/10/2025
Phase III
PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC)
2025-522109-39-00Alcoholic hepatitis
Centre Hospitalier Universitaire De Lille
Digestive System Diseases
France
17/10/2025
Phase III
PRODIGE 118 - PEHRICCA : PErioperative CISGEM plus RILVEGOSTOMIG in High-Risk resectable Intrahepatic CholangioCarcinoma Phase II single arm study -mutlicenter
2025-521302-17-00Hihg risk of cholangiocarcinoma intra hépatic resectable
Fondation Franc.Cancerologie Digestive
Neoplasms
France
15/10/2025
Phase II
A phase 2, two-part study to assess the safety, antiviral biomarker responses, and efficacy of inhaled SNG001 for the treatment of patients with a confirmed respiratory virus infection undergoing invasive mechanical ventilation
2024-520375-27-00Lower respiratory tract viral infections
Synairgen Research Limited
Virus Diseases
Netherlands, France, Spain, Belgium
15/10/2025
Phase III
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03).
2024-516906-47-00Locally Advanced or Metastatic Urothelial Carcinoma
DrugsDato-DXd·Cisplatin·Carboplatin
Daiichi Sankyo Inc.
Neoplasms
Netherlands, Germany, Norway, Denmark, France, Austria, Italy, Spain, Belgium, Czechia, Greece
15/10/2025
Phase III
B7981027 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA
2024-515438-33-00Alopecia areata
Pfizer Inc.
Immune System Diseases
Spain, France, Czechia, Italy, Poland
14/10/2025
Phase III
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
2024-519917-72-00Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloid…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
France, Germany, Italy, Greece, Belgium, Portugal, Netherlands, Austria, Sweden, Denmark, Spain, Czechia, Hungary, Ireland, Romania, Norway, Poland, Slovakia
14/10/2025
Phase III
B7981028 - A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
2024-515439-31-00Alopecia areata
Pfizer Inc.
Immune System Diseases
Italy, France, Czechia, Poland, Spain
14/10/2025
Phase III
J2O-MC-EKBG: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event - MOVE-Lp(a)
2025-521067-13-00Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASC…
Eli Lilly & Co.
Cardiovascular Diseases
Italy, Poland, Germany, Austria, Romania, Spain, Czechia, France, Denmark, Greece, Hungary, Slovakia, Belgium, Netherlands
13/10/2025
Phase III
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)
2025-521785-10-00Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited
Neoplasms
Austria, Netherlands, Belgium, Denmark, France, Germany, Spain
13/10/2025
Phase II
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage. The INFINITE Study
2025-521923-58-00Intracerebral hemorrhage.
Centre Hospitalier Universitaire De Toulouse
Nervous System Diseases
France
10/10/2025
Phase I
A phase 1, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) and Evaluation of Potential Drug-Drug Interactions.
2025-522915-40-00Healthy volunteers, Impaired renal function and suspected M…
ENYO Pharma
Digestive System Diseases
France
09/10/2025
Phase III
Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
2023-505349-26-00Out-of-hospital cardiac arrest.
CHRU De Nancy
Cardiovascular Diseases
France
08/10/2025
Phase IV
Influence of patient’s morphological characteristics on pharmacokinetic and toxicity of trastuzumab-deruxtecan administered for metastatic breast cancers (TDXdose)
2025-522656-68-00Metastatic breast cancers
Oncopole Claudius Regaud
Neoplasms
France
08/10/2025
Phase II
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
2024-519258-35-00stomach cancer, Esophage, gastro-oesophageal junction adeno…
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
08/10/2025
Phase II
PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer
2025-522108-26-00métastatique colorectal cancer
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
08/10/2025
Phase II
GFM-VEXAS-MMB: A single-arm phase II with safety run-in multicenter study of momelotinib in patients with VEXAS syndrome with or without associated myelodysplastic syndrome
2024-519779-24-00VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOM…
Groupe Francophone Des Myelodysplasies
Immune System Diseases
France
08/10/2025
Phase II
C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)
2024-518438-94-00Heart failure
Pfizer Inc.
Cardiovascular Diseases
France, Spain, Bulgaria, Poland, Hungary, Czechia
08/10/2025
Phase II
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
2025-521277-14-00Non-muscle invasive bladder cancer (NMIBC)
Tyra Biosciences Inc.
Neoplasms
Italy, Spain, France
08/10/2025
Phase III
ETOP 27-23 ARCH – A randomised phase III trial of adjuvant cemiplimab in patients with resected stage IIA-IIIB NSCLC who have not received prior adjuvant chemotherapy.
2024-519901-36-00Patients with resected stage IIA-IIIB non-small cell lung c…
ETOP IBCSG Partners Foundation
Neoplasms
France, Estonia, Spain, Austria, Italy, Germany, Ireland
08/10/2025
Phase III
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
2024-519530-24-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Norway, France, Italy, Germany, Poland
07/10/2025
Phase II
CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
2025-521161-27-00Children and adolescents with severe neurodevelopmental dis…
DrugCannabidiol
Assistance Publique Hopitaux De Paris
Behavior and Behavior Mechanisms
France
07/10/2025
Phase III
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
2024-518385-26-01Polymyalgia Rheumatica (PMR)
Centre Hospitalier Regional Et Universitaire De Brest
Immune System Diseases
France
07/10/2025
Phase III
Functional lung avoidance planning guided by lung perfusion PET/CT versus anatomical planning for lung stereotactic body radiotherapy: a double blinded, randomized, controlled trial
2024-519465-22-01planned to be treated in the radiotherapy department of the…
Centre Hospitalier Regional Et Universitaire De Brest
Respiratory Tract Diseases
France
07/10/2025
Phase I
Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis
2024-518288-37-00Lupus Nephritis
Regeneron Pharmaceuticals Inc.
Immune System Diseases
Spain, France, Germany
07/10/2025
Phase III
A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment
2025-522070-36-00immune thrombocytopenia (ITP)
DrugRilzabrutinib
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
France, Spain, Italy, Germany, Czechia, Poland, Hungary, Austria, Norway
07/10/2025
Phase IV
TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial
2025-520940-14-00Pyogenic liver abscess
DrugsDaptomycin·Colistin·Imipenem·Amikacin
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
06/10/2025
Phase II
A Phase 2, Multicenter, Open-Label Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE)
2024-519278-37-00Systemic Lupus Erythematosus, Lupus Nephritis
Celgene Corp.
Immune System Diseases
France, Spain, Portugal, Germany, Belgium, Poland, Italy, Denmark, Austria
06/10/2025
Phase III
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)
2025-521775-31-00Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
DrugsZipalertinib·Cisplatin·Carboplatin
Taiho Oncology Inc.
Neoplasms
Germany, Poland, Spain, France, Belgium, Italy, Greece, Romania, Netherlands
06/10/2025
Phase III
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01).
2024-519654-37-00Recurrent or Metastatic Head and Neck Squamous Cell Carcino…
Bicara Therapeutics Inc.
Neoplasms
Belgium, Austria, Italy, Poland, Spain, Germany, Czechia, Ireland, Greece, France, Portugal
06/10/2025
Phase III
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2-overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer. (DESTINY-Lung06)
2024-515658-26-00Unresectable or Metastatic HER2 overexpressing and PD-L1 TP…
Daiichi Sankyo Inc.
Neoplasms
France, Belgium, Germany, Portugal, Italy, Greece, Romania, Spain, Poland
06/10/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
2024-516652-18-00Atherosclerotic cardiovascular disease (ASCVD) and obesity …
Amgen Inc.
Cardiovascular Diseases
Slovakia, Denmark, Portugal, Czechia, Poland, Greece, Bulgaria, France, Spain, Sweden, Finland, Belgium, Romania, Germany, Hungary, Netherlands, Italy, Austria
06/10/2025
Phase II
A Phase 1b/2 Open-Label, Multicenter Study of Zoldonrasib (RMC-9805) with or without Daraxonrasib (RMC-6236), in Combination with Other Anticancer Agents, in Patients with RAS G12D-Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol C
2025-521147-21-00Lung Cancer
DrugsRMC-9805·Cetuximab·Pemetrexed·Cisplatin
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Austria, France, Netherlands, Czechia, Greece, Italy, Spain, Denmark
06/10/2025
Phase I/II
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
2024-517140-65-00Multiple Myeloma (MM).
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Belgium, Portugal, Sweden, Italy, France, Poland, Germany
06/10/2025
Phase III
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis
2025-520610-58-00HIV-1 prevention
Merck Sharp & Dohme LLC
Virus Diseases
France
03/10/2025
Phase II
A Phase IIb, Multicenter, Double-Blind, Placebo-Controlled Induction Study with an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients with Moderately to Severely Active Ulcerative Colitis
2025-520690-39-00Moderately to Severely Active Ulcerative Colitis (UC)
Genentech Inc.
Digestive System Diseases
France, Italy, Czechia, Poland, Germany
03/10/2025
Phase III
A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study
2024-516576-15-00metastatic breast cancer
DrugsVinorelbine·Pertuzumab·Trastuzumab·Paclitaxel
Centre Regional Lutte Contre Le Cancer
Neoplasms
France
03/10/2025
Phase II
A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)
2025-521088-10-00Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL…
DrugBexobrutideg
Nurix Therapeutics Inc.
Neoplasms
France, Italy, Hungary, Poland
02/10/2025
Phase II
Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA trial
2024-519479-24-00metastatic colorectal cancer
Fondazione GONO G.I.
Neoplasms
Germany, France, Italy, Spain
02/10/2025
Phase II
CRYOBI study - A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious active cryoglobulinemia vasculitis refractory or intolerant to Rituximab
2023-508930-33-00Non-infectious active cryoglobulinemia vasculitis who are e…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
02/10/2025
Phase III
A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of Intravenous Brincidofovir versus Intravenous Cidofovir for Treatment of Adenovirus Infection in Pediatric and Adult Subjects After Allogeneic Hematopoietic Cell Transplantation (allo HCT)
2025-521903-28-00Adenovirus viremia
Symbio Pharmaceuticals Ltd.
Virus Diseases
Germany, Italy, France, Spain, Portugal, Austria, Sweden, Belgium
02/10/2025
Phase II
AcSé HER2_Widening treatment options among adult patients with HER2-overexpressing or mutant solid cancers
2025-522169-31-00Adult Patients with HER2-IHC3+ selected solid cancers (endo…
Unicancer
Neoplasms
France
01/10/2025
Phase II
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-521278-32-00Idiopathic Pulmonary Fibrosis (IPF)
Mediar Therapeutics Inc.
Immune System Diseases
Croatia, Ireland, Netherlands, Spain, France, Belgium
01/10/2025
Phase I/II
An open-label, Phase 1/2, multicenter study of belumosudil in children aged 1 to <18 years requiring systemic treatment for active moderate-to-severe chronic graft versus host disease (cGVHD).
2024-511508-18-00Chronic graft versus host disease.
DrugBelumosudil
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
France, Italy, Belgium, Spain, Netherlands, Germany
30/09/2025
Phase I
Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)
2024-515903-21-00Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen Inc.
Neoplasms
France, Germany, Spain, Greece, Hungary, Italy
30/09/2025
Phase II
RANDOMIZED CONTROLLED STUDY COMPARING SUFENTANIL AND KETAMINE INTRANASALLY IN THE MANAGEMENT OF SEVERE ACUTE TRAUMA-RELATED PAIN IN CHILDREN
2025-521075-31-00SEVERE ACUTE TRAUMA-RELATED PAIN
Fondation Lenval Nice
Anesthesia and Analgesia
France
30/09/2025
Phase I
FT819 in B-cell Mediated Autoimmune Diseases
2024-517397-25-00B-cell Mediated Autoimmune Diseases
Fate Therapeutics Inc.
Immune System Diseases
France, Sweden, Germany
30/09/2025
Phase III
A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)
2024-518210-81-00Advanced Hepatocellular Carcinoma
AstraZeneca AB
Neoplasms
Italy, Germany, France, Poland, Spain, Netherlands
30/09/2025
Phase IV
A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease (AEOLUS)
2025-521268-37-00Respiratory tract diseases
DrugsSalbutamol·Dupilumab
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Netherlands, Hungary, France, Germany, Austria, Spain, Poland, Sweden, Italy, Denmark
29/09/2025
Phase III
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
2025-520582-51-00Hormone receptor positive breast cancer
Merck Sharp & Dohme LLC
Neoplasms
Greece, Poland, France, Italy, Spain, Hungary, Germany
29/09/2025
Phase I
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies
2025-521600-21-00mature B-Cell malignancies
Beigene Ltd.
Neoplasms
France, Italy
29/09/2025
Phase I
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.
2025-521916-20-00Cancer
Eli Lilly & Co.
Neoplasms
Spain, France
29/09/2025
Phase I/II
A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-small Cell Lung Cancer whose Tumors Express PD-L1 with Tumor Proportion Score ≥50% Without Actionable Genomic Alterations
2024-519671-26-00Advanced or Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo Inc.
Neoplasms
Spain, France, Italy
29/09/2025
Phase III
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in Participants with Relapsed Small Cell Lung Cancer (SCLC)
2025-521627-78-00Neoplasms, Lung
Glaxosmithkline Research & Development Limited
Neoplasms
Hungary, France, Portugal, Greece, Sweden, Ireland, Poland, Bulgaria, Romania, Finland, Italy, Germany, Spain
29/09/2025
Phase III
APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
2024-520407-27-00X-Linked Protoporphyria (XLP), Erythropoietic Protoporphyri…
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Germany, Ireland, Spain, France, Norway, Netherlands, Sweden, Belgium, Italy
29/09/2025
Phase III
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
2025-520766-22-00Myotonic Dystrophy Type 1
Avidity Biosciences Inc.
Musculoskeletal Diseases
France, Denmark, Spain, Italy, Germany, Netherlands
29/09/2025
Phase II
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide.
2024-519495-83-00Digestive system diseases
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Italy, Sweden, Germany, France, Poland, Denmark, Belgium, Hungary
29/09/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
2024-518821-13-00Non-cystic Fibrosis Bronchiectasis
CSL Behring LLC
Respiratory Tract Diseases
Spain, Belgium, Germany, Greece, Denmark, Netherlands, Hungary, Italy, France, Poland
26/09/2025
Phase I
CITY
2024-520294-13-00Cutaneous T-cell lymphomas (CTCL)
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
Spain, France
26/09/2025
Phase I
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS
2024-519537-29-00Acute Myeloid Leukemia and Myelodysplastic Syndrome
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Spain
26/09/2025
Phase III
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
2024-517131-52-00Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymp…
BeOne Medicines AG
Neoplasms
France, Sweden, Czechia, Austria, Belgium, Germany, Denmark, Spain, Netherlands, Italy, Ireland, Poland
26/09/2025
Phase I/II
A phase 1/2, open label, multicenter clinical trial investigating the safety, tolerability, pharmacokinetics, and antineoplastic activity of S095035 (MAT2A inhibitor) as a single agent and in combination in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
2025-521249-25-00MTAP-deleted advanced or metastatic solid tumors
Institut De Recherches Internationales Servier IRIS
Neoplasms
Denmark, Italy, Germany, Spain, France
26/09/2025
Phase III
A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined ATMP) for bone healing in delayed union and non-union after long bone fractures (OrthoAlloUnion).
2025-520841-60-00Delayed consolidation or non-union long bone fracture
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda
Musculoskeletal Diseases
Spain, Italy, France, Germany
26/09/2025
Phase I
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2024-514152-32-00Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CL…
F. Hoffmann-La Roche AG
Neoplasms
France, Spain, Poland
25/09/2025
Phase IV
Pharmacokinetic study of the use of Nefopam 30 mg tablet in patients suffering from acute pain in rheumatology - NEFOPAIN kinetics
2025-521926-13-00Hospitalized patient with acute rheumatological pain, requi…
Centre Hospitalier Universitaire Rouen
Pathological Conditions, Signs and Symptoms
France
24/09/2025
Phase II
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects with Chronic Hepatitis B Virus Infection (B-SUPREME)
2025-521178-33-00Chronic Hepatitis B Virus Infection
Aligos Therapeutics Inc.
Virus Diseases
Spain, Italy, Bulgaria, Romania, France
24/09/2025
Phase III
EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease
2025-521188-11-00cardiovascular disease, hypertension, Type 2 diabetes
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Cardiovascular Diseases
Lithuania, Netherlands, Ireland, Romania, France, Hungary, Finland, Latvia, Austria, Germany, Greece, Italy, Sweden, Denmark, Czechia, Belgium, Slovakia, Croatia, Spain, Norway, Bulgaria, Poland, Portugal
24/09/2025
Phase III
ARGX-113-2409: A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo- Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants from 12 Years to Less Than 18 Years of Age with Chronic ITP
2025-521055-23-00Chronic Idiopathic thrombocytopenic purpura
DrugEfgartigimod PH20
Argenx
Immune System Diseases
Lithuania, Romania, Hungary, France, Italy, Spain, Poland, Germany
24/09/2025
Phase II
TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY
2024-520029-35-01ADVANCED BILIARY TRACT CARCINOMA
Centre Hospitalier Regional Universitaire
Digestive System Diseases
France
24/09/2025
Phase III
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women
2024-519655-28-00Premenopausal patients with high-risk HR-positive/HER2-nega…
DrugsLeuprorelin Acetate·Goserelin·Elacestrant·Tamoxifen
Unicancer
Neoplasms
Poland, France, Italy, Greece, Spain, Ireland, Belgium
23/09/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Felzartamab in Adults with IgA Nephropathy (299IG301 / PREVAIL)
2024-519345-30-00IgA nephropathy
Biogen Idec Research Limited
Immune System Diseases
Greece, Portugal, Spain, Croatia, Czechia, Belgium, Bulgaria, Germany, Italy, Poland, France
23/09/2025
Phase I
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
2025-520490-38-00Haemophilia A with or without inhibitors. Proposed indicati…
Novo Nordisk A/S
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Spain, Austria, Italy, Germany, Belgium, France, Portugal, Sweden
22/09/2025
Phase II
Clindamycin as an alternative to vancomycin in patients undergoing aortic cardiac surgery with extracorporeal circulation (ECC): a prospective single-center pharmacokinetic study _ CLINDAPASS
2025-521555-23-00Patients undergoing cardiac surgery with extracorporeal cir…
Centre Hospitalier Universitaire De Nantes
Bacterial Infections and Mycoses
France
22/09/2025
Phase II
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis
2024-519081-49-00Moderate to severe atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
Czechia, Netherlands, Poland, Germany, Spain, Hungary, France, Italy, Slovakia
22/09/2025
Phase I
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors
2024-519622-20-00Advanced Solid Tumors Harboring RAS Mutation(S)
F. Hoffmann-La Roche AG
Neoplasms
Germany, Netherlands, Spain, Denmark, France, Belgium
22/09/2025
Phase II
A Phase 2, Open-Label, Multicenter Study of Zoldonrasib(RMC-9805) in Previously Treated Patients with RAS G12DMutant Non-Small Cell Lung Cancer (NSCLC) – Subprotocol D
2025-521681-10-00Lung Cancer
Revolution Medicines Inc.
Respiratory Tract Diseases
Germany, Greece, Netherlands, Czechia, France, Austria, Denmark, Spain, Italy
22/09/2025
Phase III
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
2025-520554-11-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
Spain, Hungary, Portugal, Greece, Germany, Italy, Austria, Ireland, Romania, Slovakia, Netherlands, Czechia, Bulgaria, Denmark, France, Poland, Belgium
22/09/2025
Phase III
INCB018424-316: A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adolescents (6 to < 18 Years Old) With Moderate Atopic Dermatitis
2024-518156-24-00Atopic Dermatitis
Incyte Corp.
Skin and Connective Tissue Diseases
France, Germany, Spain, Belgium, Italy, Hungary, Poland
18/09/2025
Phase I
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjects
2024-512106-26-02Cognitive impairment
Vandria S.A.
Nervous System Diseases
France
17/09/2025
Phase II
A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
2024-520155-24-00Metastatic castration resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Netherlands, Austria, Germany, Italy, France, Czechia, Spain
17/09/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).
2024-517232-22-00KRAS G12C-mutant, Locally Advanced Unresectable or Metastat…
DrugsCalcium levofolinate·Calderasib·Calcium folinate·Fluorouracil
Merck Sharp & Dohme LLC
Neoplasms
Poland, Spain, Netherlands, Italy, Finland, Romania, France, Germany, Hungary
17/09/2025
Phase II
PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial
2024-519637-32-00Head and Neck Cancer
University Hospital Of Clermont-Ferrand
Otorhinolaryngologic Diseases
France
16/09/2025
Phase II
Phase II study evaluating the ability of a 5-HT4 receptor agonist, prucalopride (Resolor©), to accelerate the therapeutic efficacy of a selective serotonin reuptake inhibitor (SSRI) antidepressant: clinical proof-of-concept.
2025-521811-38-01Dépression
DrugPrucalopride
Centre Hospitalier Universitaire Grenoble Alpes
Mental Disorders
France
16/09/2025
Phase III
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy
2025-520825-19-00IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also k…
Takeda Development Center Americas Inc.
Immune System Diseases
Spain, Czechia, Austria, Hungary, Germany, Norway, Slovenia, France, Sweden, Netherlands, Poland, Italy
16/09/2025
Phase I/II
A Phase 1/2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects with Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC)
2024-514360-70-00Low-grade upper track urothelial carcinoma (LG-UTUC)
DrugNadofaragene Firadenovec
Ferring Pharmaceuticals A/S
Female Urogenital Diseases and Pregnancy Complications
Spain, France, Netherlands
16/09/2025
Phase I/II
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects with Moderate-to-Severe Active Thyroid Eye Disease
2024-514110-12-00Thyroid Eye Disease
Amgen Inc.
Eye Diseases
France, Spain, Italy, Poland, Germany, Greece
15/09/2025
Phase I
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
2025-521480-12-00Advanced solid tumors, Breast Cancer
Atavistik Bio Inc.
Neoplasms
Belgium, Italy, Spain, France
15/09/2025
Phase I
A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair
2025-522774-36-00Advanced solid tumors
Nimbus Wadjet Inc.
Neoplasms
Spain, Portugal, France, Ireland
15/09/2025
Phase I
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
2024-519727-18-00Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell …
Eli Lilly & Co.
Neoplasms
Spain, Germany, France
15/09/2025
Phase III
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in Europe
2025-520499-24-00Moderate to Severe Platysma Prominence
Merz Aesthetics GmbH
Not possible to specify
Germany, Poland, France, Spain
12/09/2025
Phase II
"H3RAKLES": Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer
2024-519624-24-00HER3-mutant and HER2-not amplified metastatic breast cancer
DrugsTucatinib·Trastuzumab
Institut Curie
Neoplasms
France
11/09/2025
Phase I
A Phase 1/1b Study of IAM1363 in HER2 Cancers
2024-519188-17-00Relapsed/refractory malignancy with documented diagnosis of…
Iambic Therapeutics Inc.
Neoplasms
Spain, France, Ireland, Italy, Netherlands
11/09/2025
Phase II
A randomized, open label, multicenter, Phase 2 study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® in combination with mFOLFOX6 and bevacizumab versus standard of care for first-line treatment of non-MSI-H/dMMR, PD-L1 positive advanced colorectal cancer.
2024-519590-19-00PD-L1 positive advanced colorectal cancer
Ono Pharmaceutical Co. Ltd.
Neoplasms
Spain, France, Italy
10/09/2025
Phase II
Phase II Study Of Tarlatamab Alone Or In Combination With Chemotherapy In Advanced Neuroendocrine Carcinomas Of The Digestive System Or Unknown Primary Origin
2024-514327-42-00Advanced neuroendocrine carcinomas (NECs) of the digestive …
Grupo Espanol De Tumores Neuroendocrinos
Neoplasms
Spain, France
10/09/2025
Phase II
Phase 2 Study of Zelenectide Pevedotin in Participants with Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
2025-521115-40-00Advanced or Metastatic Non-small Cell Lung Cancer
Bicycletx Limited
Neoplasms
Italy, Spain, France, Germany
09/09/2025
Phase II
GRACIE : Phase II study evaluating ivonescimab in combination with chemotherapy for first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients
2025-520694-39-00Metastatic or locally advanced irresectable (stage IV) gast…
Unicancer
Neoplasms
France
08/09/2025
Phase III
A Phase 3 Randomized, Controlled Study to Assess the Efficacy and Safety of NVD003 compared with Iliac Crest Bone Graft in Pediatric Participants Treated Surgically for Congenital Pseudarthrosis of the Tibia
2025-520998-39-00Congenital pseudarthrosis of the tibia
Novadip Biosciences
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Belgium
08/09/2025
Phase II
A Phase 2 Study to Evaluate the Safety and Efficacy of Atacicept in Multiple Autoimmune Glomerular Diseases (PIONEER)
2024-518465-10-00Multiple Autoimmune Glomerular Diseases
Vera Therapeutics Inc.
Pathological Conditions, Signs and Symptoms
Germany, France, Italy, Spain, Poland, Belgium
08/09/2025
Phase III
An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study
2025-521096-31-00Chronic Hepatitis C Virus (HCV) Infection
Atea Pharmaceuticals Inc.
Virus Diseases
Romania, France, Germany, Greece, Poland, Spain
08/09/2025
Phase III
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
2025-521478-32-00PEDIATRIC ACUTE MYOCARDITIS
DrugAnakinra
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
04/09/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease
2024-518296-56-00Crohn’s Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Digestive System Diseases
Spain, Austria, Lithuania, France, Belgium, Germany, Sweden, Czechia, Finland, Croatia, Latvia, Portugal, Netherlands, Italy, Denmark, Slovakia, Romania, Poland, Ireland, Hungary, Greece
03/09/2025
Phase II
NEOSTART Study - NEOADJUVANT PEMBROLIZUMAB IN PATIENTS WITH HIGH RISK, STAGE IIB/IIC CUTANEOUS MELANOMA: A SINGLE ARM PROOF OF CONCEPT PHASE IIA STUDY
2024-519573-19-00melanoma
DrugPembrolizumab
Centre Hospitalier Regional Universitaire
Skin and Connective Tissue Diseases
France
02/09/2025
Phase III
GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas
2024-515948-23-00Advanced pulmonary or gastroenteropancreatic poorly differe…
Intergroupe Francophone De Cancerologie Thoracique
Neoplasms
France
02/09/2025
Phase IV
Evaluation of the effect of adrenalized lidocaine with or without bicarbonate on early postoperative recovery in ambulatory hand and foot surgery with WALANT: A Single-centre prospective randomised double-blind non-inferiority study.
2024-519650-36-00Hand Surgery, Foot surgery
Centre Hospitalier Universitaire De Nimes
Anesthesia and Analgesia
France
02/09/2025
Phase III
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
2024-520050-38-00Extensive stage small cell lung cancer (ES-SCLC). …
DrugsSiltuximab·Mycophenolate Mofetil·Tarlatamab·Infliximab
Amgen Inc.
Neoplasms
Portugal, Germany, Spain, Italy, Denmark, Netherlands, France, Austria, Greece, Belgium, Hungary, Poland, Romania
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine (MINT-C)
2024-515682-34-00Chronic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Spain, Denmark, France, Germany, Slovakia, Austria, Italy, Poland, Czechia
01/09/2025
Phase III
A phase 3, randomised, multi-center, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin therapy (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)
2024-512177-27-01High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-m…
Ferring Pharmaceuticals A/S
Male Urogenital Diseases
Spain, Denmark, Poland, Czechia, France
01/09/2025
Phase III
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine (MINT-E)
2024-515715-22-00Episodic migraine
Merz Therapeutics GmbH
Nervous System Diseases
Italy, Austria, Poland, Germany, France, Spain, Slovakia, Denmark, Czechia
01/09/2025
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00Hidradenitis suppurativa (HS)
MoonLake Immunotherapeutics AG
Skin and Connective Tissue Diseases
Norway, Hungary, Spain, France, Germany, Poland, Czechia, Slovakia, Bulgaria, Netherlands, Italy, Portugal, Belgium
29/08/2025
Phase III
Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD
2024-516610-38-00Parkinson's disease, Prodromal phase of Parkinson's disease
Institut National De La Sante Et De La Recherche Medicale
Nervous System Diseases
France
29/08/2025
Phase I
Etude de bioéquivalence entre Circadin et Melatonin PILEJE LP 2 mg
2024-519932-17-00Primary insomnia characterized by poor quality of sleep
Pileje
Hormonal diseases
France
28/08/2025
Phase I
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
2024-519157-10-00Systemic Lupus Erythematosus, Sjogren's disease
AbbVie Deutschland GmbH & Co. KG
Immune system processes
Netherlands, France
28/08/2025
Rows per page Showing 501–917 of 917
Previous 1 2
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-europe/country/france?page=2

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,561 trial records at the last sync on 06 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 917 of those trials with a site in France.

How many recently authorised EU trials have a site in France?

917 of the 2,557 most recently authorised trials in this register list a site in France; 425 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.